Top

Graefe's Archive for Clinical and Experimental Ophthalmology

26-04-2024 | Dexamethasone | Retinal Disorders

Switching to subtenon triamcinolone acetonide does not jeopardize the functional and anatomic outcomes of dexamethasone implant treated eyes with diabetic macular edema

Authors: Ysé Borella, Samuel Bertaud, Ramin Tadayoni, Bahram Bodaghi, Bénédicte Dupas, Sara Touhami

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology

Abstract

Background

Intraocular dexamethasone implant (DEXi) is an efficient treatment for diabetic macular edema (DME). However, it may be unavailable or contraindicated. Triamcinolone acetonide is another corticosteroid that has proved to be safe and effective in treating macular edema complicating various diseases including diabetes. The purpose of this study is to evaluate the outcomes of a switch from DEXi to subtenon triamcinolone acetonide (STTA) and back, in eyes with DME.

Methods

Retrospective study. DME eyes that had been treated with DEXi and switched to STTA between October 2018 and February 2019 (stock shortage of DEXi) were included. The functional and anatomical outcomes of the switch and switch-back were studied.

Results

26 eyes of 17 patients (mean age 67.1 ± 8.2 years) were considered. The mean baseline visual acuity (VA) was 0.35 ± 0.17 decimals remaining stable after DEXi, STTA and switch-back to DEXi. The mean central macular thickness (CMT) was 492.7 ± 32.8 µm initially, decreasing to 294.3 ± 133.4 µm after DEXi, 369.9 ± 182.3 µm after STTA and 297.6 ± 72.0 µm after switching back to DEXi (all p < 0.05 versus baseline). Compared to baseline, the CMT reduction was numerically better after DEXi and switching back to DEXi than after STTA (mean reduction: -200.4 µm, -167.7 µm, and -95.08 µm respectively, p = 0.13). Intraocular pressure was comparable after DEXi and STTA.

Conclusion

DEXi is the steroid of choice in DME. However, STTA can be a cost-effective alternative when DEXi is unavailable or contraindicated. This study suggests that STTA may be used in the context of a step therapy in DME.

Antcliff RJ, Marshall J (1999) The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 14:223–232. https://doi.org/10.3109/08820539909069541CrossRefPubMed

Bressler NM, Beaulieu WT, Maguire MG et al (2018) Early Response to Anti-Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes with Diabetic Macular Edema in Protocol T. Am J Ophthalmol 195:93–100. https://doi.org/10.1016/j.ajo.2018.07.030CrossRefPubMedPubMedCentral

Munk MR, Somfai GM, de Smet MD et al (2022) The Role of Intravitreal Corticosteroids in the Treatment of DME: Predictive OCT Biomarkers. Int J Mol Sci 23:7585. https://doi.org/10.3390/ijms23147585CrossRefPubMedPubMedCentral

Vujosevic S, Toma C, Villani E et al (2020) Diabetic macular edema with neuroretinal detachment: OCT and OCT-angiography biomarkers of treatment response to anti-VEGF and steroids. Acta Diabetol 57:287–296. https://doi.org/10.1007/s00592-019-01424-4CrossRefPubMed

Zhang J, Zhang J, Zhang C et al (2022) Diabetic Macular Edema: Current Understanding. Mol Mech Therapeutic Implications Cells 11:3362. https://doi.org/10.3390/cells11213362CrossRef

Maturi RK, Glassman AR, Liu D et al (2018) Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial. JAMA Ophthalmol 136:29–38. https://doi.org/10.1001/jamaophthalmol.2017.4914CrossRefPubMed

Castro-Navarro V, Cervera-Taulet E, Navarro-Palop C et al (2019) Intravitreal dexamethasone implant Ozurdex® in naïve and refractory patients with different subtypes of diabetic macular edema. BMC Ophthalmol 19:15. https://doi.org/10.1186/s12886-018-1022-9CrossRefPubMedPubMedCentral

Boyer DS, Yoon YH, Belfort R et al (2014) Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 121:1904–1914. https://doi.org/10.1016/j.ophtha.2014.04.024CrossRefPubMed

Patil NS, Mihalache A, Hatamnejad A et al (2023) Intravitreal Steroids Compared with Anti-VEGF Treatment for Diabetic Macular Edema: A Meta-Analysis. Ophthalmol Retina 7:289–299. https://doi.org/10.1016/j.oret.2022.10.008CrossRefPubMed

10.

Jhaveri CD, Glassman AR, Ferris FL et al (2022) Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema. N Engl J Med 387:692–703. https://doi.org/10.1056/NEJMoa2204225CrossRefPubMedPubMedCentral

11.

Erden B, Çakır A, Aslan AC et al (2019) The Efficacy of Posterior Subtenon Triamcinolone Acetonide Injection in Treatment of Irvine-Gass Syndrome. Ocul Immunol Inflamm 27:1235–1241. https://doi.org/10.1080/09273948.2019.1620786CrossRefPubMed

12.

Choopong P, Taetrongchit N, Boonsopon S et al (2022) Efficacy of subtenon 20-mg triamcinolone injection versus 0.1% dexamethasone eye drops for controlling inflammation after phacoemulsification: a randomized controlled trial. Sci Rep 12:16471. https://doi.org/10.1038/s41598-022-20522-yCrossRefPubMedPubMedCentral

13.

Ozkurt YB, Akkaya S, Aksoy S et al (2015) Posterior Subtenon’s Capsule Triamcinolone Acetonide Injection for the Treatment of Diabetic Macular Edema. J Ocul Pharmacol Ther 31:455–460. https://doi.org/10.1089/jop.2014.0130CrossRefPubMed

14.

Jung JL, Harasawa M, Patnaik JL, Palestine AG (2022) Subtenon Triamcinolone Acetonide Injection with Topical Anesthesia in Pediatric Non-Infectious Uveitis. Ophthalmol Ther 11:811–820. https://doi.org/10.1007/s40123-022-00480-4CrossRefPubMedPubMedCentral

15.

Erdogan G, Gumus G, Gunay BO, Ozkaya A (2023) Posterior sub-Tenon triamcinolone injection in the treatment of postoperative cystoid macular edema secondary to pars plana vitrectomy. Indian J Ophthalmol 71:174–179. https://doi.org/10.4103/ijo.IJO_621_22CrossRefPubMed

16.

Carbonnière C, Couret C, Blériot A et al (2017) Treatment of macular edema: Comparison of efficacy and tolerability of subconjunctival triamcinolone injections, sub-tenon’s triamcinolone injections and intravitreal dexamethasone implant. J Fr Ophtalmol 40:177–186. https://doi.org/10.1016/j.jfo.2016.11.013CrossRefPubMed

17.

Thorne JE, Sugar EA, Holbrook JT et al (2019) Periocular Triamcinolone vs. Intravitreal Triamcinolone vs. Intravitreal Dexamethasone Implant for the Treatment of Uveitic Macular Edema: The PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial. Ophthalmology 126:283–295. https://doi.org/10.1016/j.ophtha.2018.08.021CrossRefPubMed

18.

Gumus G, Erdogan G, Gunay BO, Karatas Durusoy G (2022) Comparison of Intravitreal Dexamethasone Implant and Posterior Subtenon Triamcinolone Injection in the Treatment of Diabetic Macular Edema in Vitrectomized Eyes. Ophthalmologica 245:439–445. https://doi.org/10.1159/000526172CrossRefPubMed

19.

He Y, Ren X-J, Hu B-J et al (2018) A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema. BMC Ophthalmol 18:121. https://doi.org/10.1186/s12886-018-0779-1CrossRefPubMedPubMedCentral

20.

Ehlers JP, Yeh S, Maguire MG et al (2022) Intravitreal Pharmacotherapies for Diabetic Macular Edema: A Report by the American Academy of Ophthalmology. Ophthalmology 129:88–99. https://doi.org/10.1016/j.ophtha.2021.07.009CrossRefPubMed

21.

Bux AV, Fortunato F, Barone A et al (2022) Early treatment with dexamethasone intravitreal implants in diabetic macular edema: Naïve versus refractory patients. Eur J Ophthalmol 32:1619–1626. https://doi.org/10.1177/11206721211024804CrossRefPubMed

22.

Callanan DG, Loewenstein A, Patel SS et al (2017) A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 255:463–473. https://doi.org/10.1007/s00417-016-3472-1CrossRefPubMed

23.

Cellini M, Pazzaglia A, Zamparini E et al (2008) Intravitreal vs. subtenon triamcinolone acetonide for the treatment of diabetic cystoid macular edema. BMC Ophthalmol 8:5. https://doi.org/10.1186/1471-2415-8-5CrossRefPubMedPubMedCentral

24.

Choi YJ, Oh IK, Oh JR, Huh K (2006) Intravitreal versus posterior subtenon injection of triamcinolone acetonide for diabetic macular edema. Korean J Ophthalmol 20:205–209. https://doi.org/10.3341/kjo.2006.20.4.205CrossRefPubMedPubMedCentral

25.

Kurt MM, Çekiç O, Akpolat Ç et al (2017) Vessel diameter study: intravitreal vs posterior subtenon triamcinolone acetonide injection for diabetic macular edema. Eye (Lond) 31:1155–1162. https://doi.org/10.1038/eye.2017.46CrossRefPubMed

26.

Bakri SJ, Kaiser PK (2005) Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema. Am J Ophthalmol 139:290–294. https://doi.org/10.1016/j.ajo.2004.09.038CrossRefPubMed

27.

Kim MW, Moon H, Yang SJ, Joe SG (2016) Effect of Posterior Subtenon Triamcinolone Acetonide Injection on Diabetic Macular Edema Refractory to Intravitreal Bevacizumab Injection. Korean J Ophthalmol 30:25–31. https://doi.org/10.3341/kjo.2016.30.1.25CrossRefPubMedPubMedCentral

28.

Liu B, Ma G, Hou J, Cong C (2022) Choroidal Structural Changes of Posterior Subtenon Triamcinolone Acetonide Injection in Eyes with Refractory Diabetic Macular Edema. J Ophthalmol 2022:6882607. https://doi.org/10.1155/2022/6882607CrossRefPubMedPubMedCentral

29.

Shimura M, Yasuda K, Minezaki T, Noma H (2016) Reduction in the frequency of intravitreal bevacizumab administrations achieved by posterior subtenon injection of triamcinolone acetonide in patients with diffuse diabetic macular edema. Jpn J Ophthalmol 60:401–407. https://doi.org/10.1007/s10384-016-0458-9CrossRefPubMed

30.

Inoue M, Takeda K, Morita K et al (2004) Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection. Am J Ophthalmol 138:1046–1048. https://doi.org/10.1016/j.ajo.2004.05.028CrossRefPubMed

31.

Ogura Y, Shimura M, Iida T et al (2019) Phase II/III Clinical Trial of Sub-Tenon Injection of Triamcinolone Acetonide (WP-0508ST) for Diabetic Macular Edema. Ophthalmologica 241:161–169. https://doi.org/10.1159/000492135CrossRefPubMed

32.

Rosenblatt A, Udaondo P, Cunha-Vaz J et al (2020) A Collaborative Retrospective Study on the Efficacy and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema: The European DME Registry Study. Ophthalmology 127:377–393. https://doi.org/10.1016/j.ophtha.2019.10.005CrossRefPubMed

33.

Dutra Medeiros M, Alkabes M, Nucci P (2014) Effectiveness of the Dexamethasone Intravitreal Implant for Treatment of Patients with Diabetic Macular Oedema. Eur Endocrinol 10:111–116. https://doi.org/10.17925/EE.2014.10.02.111CrossRefPubMedPubMedCentral

34.

Xia H-H, Chen J-L, Chen H-Y, Lin H-J (2020) Correlation between optical coherence tomography, multifocal electroretinogram findings and visual acuity in diabetic macular edema. Int J Ophthalmol 13:1592–1596. https://doi.org/10.18240/ijo.2020.10.13CrossRefPubMedPubMedCentral

35.

Shen Y, Liu K, Xu X (2016) Correlation Between Visual Function and Photoreceptor Integrity in Diabetic Macular Edema: Spectral-Domain Optical Coherence Tomography. Curr Eye Res 41:391–399. https://doi.org/10.3109/02713683.2015.1019003CrossRefPubMed

36.

Abd Elhamid AH (2019) Quantitative Assessment of Outer Retinal Layer and Photoreceptor Outer Segment Layer and Their Relation to Visual Acuity in Diabetic Macular Edema. J Ophthalmol 2019:8216150. https://doi.org/10.1155/2019/8216150CrossRefPubMedPubMedCentral

37.

Toda J, Fukushima H, Kato S (2009) Systemic complications of posterior subtenon injection of triamcinolone acetonide in type 2 diabetes patients. Diabetes Res Clin Pract 84:e38-40. https://doi.org/10.1016/j.diabres.2008.10.020CrossRefPubMed

38.

Kaderli B, Kivanc SA, Inan UU et al (2014) Effect of posterior subtenon injection of 40 mg of triamcinolone acetonide on glycemic control and serum cortisol and adrenocorticotropic hormone in diabetic patients. Eur Rev Med Pharmacol Sci 18:2609–2614PubMed

39.

Karti O, Saatci AO (2021) Place of intravitreal dexamethasone implant in the treatment armamentarium of diabetic macular edema. World J Diabetes 12:1220–1232. https://doi.org/10.4239/wjd.v12.i8.1220CrossRefPubMedPubMedCentral

40.

Mehta H, Hennings C, Gillies MC et al (2018) Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database Syst Rev 4:CD01599. https://doi.org/10.1002/14651858.CD011599.pub2CrossRef

41.

Yang Y-H, Kuo H-H, Hsu W-C, Hsieh Y-T (2020) Ocular hypertension and severe intraocular pressure elevation after posterior subtenon injection of triamcinolone acetonide for various diseases. Int J Ophthalmol 13:946–951. https://doi.org/10.18240/ijo.2020.06.14CrossRefPubMedPubMedCentral

42.

Base de données publique des médicaments. https://base-donnees-publique.medicaments.gouv.fr/

43.

Tripathy K (2023) Commentary: Posterior subtenon triamcinolone - The unsung hero for managing various ocular disorders. Indian J Ophthalmol 71:181–182. https://doi.org/10.4103/ijo.IJO_1963_22CrossRefPubMedPubMedCentral

Title: Switching to subtenon triamcinolone acetonide does not jeopardize the functional and anatomic outcomes of dexamethasone implant treated eyes with diabetic macular edema
Authors: Ysé Borella
Samuel Bertaud
Ramin Tadayoni
Bahram Bodaghi
Bénédicte Dupas
Sara Touhami
Publication date: 26-04-2024
Publisher: Springer Berlin Heidelberg
Keywords: Dexamethasone
Edema
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-024-06492-z

At a glance: The STEP trials

Springer Medicine

Switching to subtenon triamcinolone acetonide does not jeopardize the functional and anatomic outcomes of dexamethasone implant treated eyes with diabetic macular edema

Abstract

Background

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content